IMMUNOTherapy INDUCED DM

Question 1

What condition is associated with immunotherapy-induced type 1 diabetes mellitus?

Answer 1

Immunotherapy-induced type 1 diabetes mellitus

This condition occurs as a result of immune system modulation through therapies.

Question 2

What treatments are linked to the onset of immunotherapy-induced type 1 diabetes?

Answer 2

Nivolumab and ipilimumab

These are immune checkpoint inhibitors used in cancer therapy.

Question 3

What percentage of patients with new-onset type 1 diabetes experience diabetic ketoacidosis (DKA)?

Answer 3

76%

DKA is a severe metabolic complication of diabetes.

Question 4

What is the risk percentage range for endocrine adverse effects due to immune checkpoint blockade?

Answer 4

4%-30%

Endocrine adverse effects can lead to various hormonal imbalances.

Question 5

What is the incidence of autoimmune diabetes mellitus among patients undergoing immunotherapy?

Answer 5

1%

Though rare, autoimmune diabetes can be life-threatening.

Question 6

What is the median onset time for diabetes after starting immune checkpoint inhibitors?

Answer 6

49 days

Onset can vary significantly, ranging from 5 to 448 days.

Question 7

What percentage of patients develop new-onset type 1 diabetes within 3 months of first exposure?

Answer 7

71%

This suggests a relatively quick onset following treatment initiation.

Question 8

What type of antibodies are present in 50% of cases of immunotherapy-induced type 1 diabetes?

Answer 8

Type 1 diabetes antibodies, primarily glutamic acid decarboxylase 65 antibodies

These antibodies are indicative of autoimmune destruction of pancreatic beta cells.

Question 9

Are patients with immunotherapy-induced type 1 diabetes insulin-dependent?

Answer 9

Yes, all patients are insulin-deficient and require permanent exogenous insulin treatment

Basal and mealtime insulins cannot be stopped or reduced.

Question 10

PD1 VS PI3 INHIBITOR IN IMMUNOTHERAPY INDUCED DM?

Answer 10